insights_auto
Why is ONCY down 2.97%?
Dive Deeperchevron_right
ONCY:NASDAQ
Oncolytics Biotech Inc
$0.66
arrow_downward
-2.97%(-0.020) 1D
$0.68
arrow_upward
+1.99% (+0.013)bedtimeAfter hours
Closed: Sep 28, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ONCY...
Open
$0.68
High
$0.72
Low
$0.66
Mkt. cap
84.95M
Avg. vol.
955.26K
Volume
1.13M
52-wk high
$1.51
52-wk low
$0.64
Beta
1.15
Shares outstanding
127.51M
No. of employees
29
Open
$0.68
High
$0.72
Low
$0.66
Mkt. cap
84.95M
Avg. vol.
955.26K
Volume
1.13M
52-wk high
$1.51
52-wk low
$0.64
Beta
1.15
Shares outstanding
127.51M
No. of employees
29
News stories
From web sources and news partners
GuruFocus
·
9 hours ago
Oncolytics Biotech (ONCY) Advances Clinical Trial for Metastatic Colorectal Cancer Pelareorep Treatment
TipRanks
·
10 hours ago
Oncolytics Advances Pelareorep Trial, Gains FDA Alignment
Investing.com Canada
·
10 hours ago
Form 8K Oncolytics Biotech Inc. For: 28 September By Investing.com
Profile
Oncolytics Biotech Inc. is a biotech company headquartered in San Diego, California, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Wikipedia
About Oncolytics Biotech Inc
CEO-
Employees29
Founded1998
HeadquartersCalgary, Alberta, Canada
SectorBiotechnology
Websiteoncolyticsbiotech.com